Implementing best practices on data generation and reporting of Mycobacterium tuberculosis in vitro assays within the ERA4TB consortium
Summary: Tuberculosis (TB) is the historical leading cause of death by a single infectious agent. The European Regimen Accelerator for Tuberculosis (ERA4TB) is a public-private partnership of 30+ institutions with the objective to progress new anti-TB regimens into the clinic. Thus, robust and repli...
| Príomhchruthaitheoirí: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Formáid: | Alt |
| Teanga: | English |
| Foilsithe / Cruthaithe: |
Elsevier
2023-04-01
|
| Sraith: | iScience |
| Ábhair: | |
| Rochtain ar líne: | http://www.sciencedirect.com/science/article/pii/S2589004223004881 |
| _version_ | 1827971920068345856 |
|---|---|
| author | Rob C. van Wijk Ainhoa Lucía Pavan Kumar Sudhakar Lindsay Sonnenkalb Cyril Gaudin Eik Hoffmann Bérénice Dremierre Diana Angélica Aguilar-Ayala Michael Dal Molin Jan Rybniker Stefano de Giorgi Laura Cioetto-Mazzabò Greta Segafreddo Riccardo Manganelli Giulia Degiacomi Deborah Recchia Maria Rosalia Pasca Ulrika S.H. Simonsson Santiago Ramón-García |
| author_facet | Rob C. van Wijk Ainhoa Lucía Pavan Kumar Sudhakar Lindsay Sonnenkalb Cyril Gaudin Eik Hoffmann Bérénice Dremierre Diana Angélica Aguilar-Ayala Michael Dal Molin Jan Rybniker Stefano de Giorgi Laura Cioetto-Mazzabò Greta Segafreddo Riccardo Manganelli Giulia Degiacomi Deborah Recchia Maria Rosalia Pasca Ulrika S.H. Simonsson Santiago Ramón-García |
| author_sort | Rob C. van Wijk |
| collection | DOAJ |
| description | Summary: Tuberculosis (TB) is the historical leading cause of death by a single infectious agent. The European Regimen Accelerator for Tuberculosis (ERA4TB) is a public-private partnership of 30+ institutions with the objective to progress new anti-TB regimens into the clinic. Thus, robust and replicable results across independent laboratories are essential for reliable interpretation of treatment efficacy. A standardization workgroup unified in vitro protocols and data reporting templates. Time-kill assays provide essential input data for pharmacometric model-informed translation of single agents and regimens activity from in vitro to in vivo and the clinic. Five conditions were assessed by time-kill assays in six independent laboratories using four bacterial plating methods. Baseline bacterial burden varied between laboratories but variability was limited in net drug effect, confirming 2.5 μL equally robust as 100 μL plating. This exercise establishes the foundations of collaborative data generation, reporting, and integration within the overarching Antimicrobial Resistance Accelerator program. |
| first_indexed | 2024-04-09T19:15:01Z |
| format | Article |
| id | doaj.art-cad837fcee6d48d4aec14cd52a9d0e2a |
| institution | Directory Open Access Journal |
| issn | 2589-0042 |
| language | English |
| last_indexed | 2024-04-09T19:15:01Z |
| publishDate | 2023-04-01 |
| publisher | Elsevier |
| record_format | Article |
| series | iScience |
| spelling | doaj.art-cad837fcee6d48d4aec14cd52a9d0e2a2023-04-06T06:12:34ZengElsevieriScience2589-00422023-04-01264106411Implementing best practices on data generation and reporting of Mycobacterium tuberculosis in vitro assays within the ERA4TB consortiumRob C. van Wijk0Ainhoa Lucía1Pavan Kumar Sudhakar2Lindsay Sonnenkalb3Cyril Gaudin4Eik Hoffmann5Bérénice Dremierre6Diana Angélica Aguilar-Ayala7Michael Dal Molin8Jan Rybniker9Stefano de Giorgi10Laura Cioetto-Mazzabò11Greta Segafreddo12Riccardo Manganelli13Giulia Degiacomi14Deborah Recchia15Maria Rosalia Pasca16Ulrika S.H. Simonsson17Santiago Ramón-García18Department of Pharmaceutical Biosciences, Uppsala University, 75124 Uppsala, SwedenDepartment of Microbiology, Faculty of Medicine, University of Zaragoza, 50009 Zaragoza, Spain; CIBER Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, 28029 Madrid, SpainData collaboration center, Critical Path Institute Ltd, D11 YNR2 Dublin, IrelandMolecular and Experimental Mycobacteriology, Research Center Borstel Leibniz Lung Center, 23845 Borstel, GermanyCenter for Infection and Immunity of Lille, Institut Pasteur de Lille, 59019 Lille, FranceCenter for Infection and Immunity of Lille, Institut Pasteur de Lille, 59019 Lille, FranceCenter for Infection and Immunity of Lille, Institut Pasteur de Lille, 59019 Lille, FranceDepartment of Microbiology, Faculty of Medicine, University of Zaragoza, 50009 Zaragoza, SpainDepartment I of Internal Medicine, Division of Infectious Diseases, University of Cologne, 50937 Cologne, Germany; Faculty of Medicine, Center for Molecular Medicine Cologne (CMMC), University of Cologne, 50931 Cologne, GermanyDepartment I of Internal Medicine, Division of Infectious Diseases, University of Cologne, 50937 Cologne, Germany; Faculty of Medicine, Center for Molecular Medicine Cologne (CMMC), University of Cologne, 50931 Cologne, Germany; German Center for Infection Research (DZIF), Partner Site Bonn-Cologne, 50931 Cologne, GermanyDepartment of Molecular Medicine, University of Padova, 35121 Padova, ItalyDepartment of Molecular Medicine, University of Padova, 35121 Padova, ItalyDepartment of Molecular Medicine, University of Padova, 35121 Padova, ItalyDepartment of Molecular Medicine, University of Padova, 35121 Padova, ItalyDepartment of Biology and Biotechnology Lazzaro Spallanzani, University of Pavia, 27100 Pavia, ItalyDepartment of Biology and Biotechnology Lazzaro Spallanzani, University of Pavia, 27100 Pavia, ItalyDepartment of Biology and Biotechnology Lazzaro Spallanzani, University of Pavia, 27100 Pavia, ItalyDepartment of Pharmaceutical Biosciences, Uppsala University, 75124 Uppsala, SwedenDepartment of Microbiology, Faculty of Medicine, University of Zaragoza, 50009 Zaragoza, Spain; CIBER Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, 28029 Madrid, Spain; Research & Development Agency of Aragon Foundation (Fundación ARAID), 50009 Zaragoza, Spain; Corresponding authorSummary: Tuberculosis (TB) is the historical leading cause of death by a single infectious agent. The European Regimen Accelerator for Tuberculosis (ERA4TB) is a public-private partnership of 30+ institutions with the objective to progress new anti-TB regimens into the clinic. Thus, robust and replicable results across independent laboratories are essential for reliable interpretation of treatment efficacy. A standardization workgroup unified in vitro protocols and data reporting templates. Time-kill assays provide essential input data for pharmacometric model-informed translation of single agents and regimens activity from in vitro to in vivo and the clinic. Five conditions were assessed by time-kill assays in six independent laboratories using four bacterial plating methods. Baseline bacterial burden varied between laboratories but variability was limited in net drug effect, confirming 2.5 μL equally robust as 100 μL plating. This exercise establishes the foundations of collaborative data generation, reporting, and integration within the overarching Antimicrobial Resistance Accelerator program.http://www.sciencedirect.com/science/article/pii/S2589004223004881TreatmentMolecular modellingBiochemical assay |
| spellingShingle | Rob C. van Wijk Ainhoa Lucía Pavan Kumar Sudhakar Lindsay Sonnenkalb Cyril Gaudin Eik Hoffmann Bérénice Dremierre Diana Angélica Aguilar-Ayala Michael Dal Molin Jan Rybniker Stefano de Giorgi Laura Cioetto-Mazzabò Greta Segafreddo Riccardo Manganelli Giulia Degiacomi Deborah Recchia Maria Rosalia Pasca Ulrika S.H. Simonsson Santiago Ramón-García Implementing best practices on data generation and reporting of Mycobacterium tuberculosis in vitro assays within the ERA4TB consortium iScience Treatment Molecular modelling Biochemical assay |
| title | Implementing best practices on data generation and reporting of Mycobacterium tuberculosis in vitro assays within the ERA4TB consortium |
| title_full | Implementing best practices on data generation and reporting of Mycobacterium tuberculosis in vitro assays within the ERA4TB consortium |
| title_fullStr | Implementing best practices on data generation and reporting of Mycobacterium tuberculosis in vitro assays within the ERA4TB consortium |
| title_full_unstemmed | Implementing best practices on data generation and reporting of Mycobacterium tuberculosis in vitro assays within the ERA4TB consortium |
| title_short | Implementing best practices on data generation and reporting of Mycobacterium tuberculosis in vitro assays within the ERA4TB consortium |
| title_sort | implementing best practices on data generation and reporting of mycobacterium tuberculosis in vitro assays within the era4tb consortium |
| topic | Treatment Molecular modelling Biochemical assay |
| url | http://www.sciencedirect.com/science/article/pii/S2589004223004881 |
| work_keys_str_mv | AT robcvanwijk implementingbestpracticesondatagenerationandreportingofmycobacteriumtuberculosisinvitroassayswithintheera4tbconsortium AT ainhoalucia implementingbestpracticesondatagenerationandreportingofmycobacteriumtuberculosisinvitroassayswithintheera4tbconsortium AT pavankumarsudhakar implementingbestpracticesondatagenerationandreportingofmycobacteriumtuberculosisinvitroassayswithintheera4tbconsortium AT lindsaysonnenkalb implementingbestpracticesondatagenerationandreportingofmycobacteriumtuberculosisinvitroassayswithintheera4tbconsortium AT cyrilgaudin implementingbestpracticesondatagenerationandreportingofmycobacteriumtuberculosisinvitroassayswithintheera4tbconsortium AT eikhoffmann implementingbestpracticesondatagenerationandreportingofmycobacteriumtuberculosisinvitroassayswithintheera4tbconsortium AT berenicedremierre implementingbestpracticesondatagenerationandreportingofmycobacteriumtuberculosisinvitroassayswithintheera4tbconsortium AT dianaangelicaaguilarayala implementingbestpracticesondatagenerationandreportingofmycobacteriumtuberculosisinvitroassayswithintheera4tbconsortium AT michaeldalmolin implementingbestpracticesondatagenerationandreportingofmycobacteriumtuberculosisinvitroassayswithintheera4tbconsortium AT janrybniker implementingbestpracticesondatagenerationandreportingofmycobacteriumtuberculosisinvitroassayswithintheera4tbconsortium AT stefanodegiorgi implementingbestpracticesondatagenerationandreportingofmycobacteriumtuberculosisinvitroassayswithintheera4tbconsortium AT lauracioettomazzabo implementingbestpracticesondatagenerationandreportingofmycobacteriumtuberculosisinvitroassayswithintheera4tbconsortium AT gretasegafreddo implementingbestpracticesondatagenerationandreportingofmycobacteriumtuberculosisinvitroassayswithintheera4tbconsortium AT riccardomanganelli implementingbestpracticesondatagenerationandreportingofmycobacteriumtuberculosisinvitroassayswithintheera4tbconsortium AT giuliadegiacomi implementingbestpracticesondatagenerationandreportingofmycobacteriumtuberculosisinvitroassayswithintheera4tbconsortium AT deborahrecchia implementingbestpracticesondatagenerationandreportingofmycobacteriumtuberculosisinvitroassayswithintheera4tbconsortium AT mariarosaliapasca implementingbestpracticesondatagenerationandreportingofmycobacteriumtuberculosisinvitroassayswithintheera4tbconsortium AT ulrikashsimonsson implementingbestpracticesondatagenerationandreportingofmycobacteriumtuberculosisinvitroassayswithintheera4tbconsortium AT santiagoramongarcia implementingbestpracticesondatagenerationandreportingofmycobacteriumtuberculosisinvitroassayswithintheera4tbconsortium |